Biolimus DCB Non-Inferior to Paclitaxel DCB in Treating DES-ISR: BIO ASCEND ISR Trial

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

Biolimus DCB Non-Inferior to Paclitaxel DCB in Treating DES-ISR: BIO ASCEND ISR Trial

Posted: 05/14/2024
Author:
Bailey Salimes, CRTonline.org
Percutaneous Devices EuroPCR News Articles Coronary Interventions Percutaneous Coronary Intervention 2024 Complex Coronary News Coronary DCB Late-Breaking Trials Restenosis

In the treatment of patients with coronary drug-eluting stent in-stent restenosis (DES-ISR), a novel biolimus-coated balloon (BCB) showed similar angiographic outcomes to the clinically proven paclitaxel-coated balloon (PCB), according to a new study.
1-3 of 4095 results
1 2 3 4 5 Next »

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

Jan 14, 2025 by
Nathan Gray, CRTonline.org

While multiple advancements in left atrial appendage occlusion (LAAO) devices have emerged for stroke prevention and arrhythmia therapy, several unanswered questions remain, specifically regarding the patient and device selection and the management of complications, according to a new review.

HF Patients With Prior MI See No Clinical Benefit from Revivent TC Anchor System vs Medical Therapy Alone: ALIVE Trial

Jan 14, 2025 by
Natalie Morrison, CRTonline.org

Heart failure patients who suffered prior myocardial infarction and anterior scarring saw no improvements in clinical outcomes when treated with the Revivent TC anchor system verses guideline-directed medical therapy alone in the ALIVE trial, despite reductions in left ventricular dimensions.

Study Proposes Demographic-Based Approach to Improve Hypertrophic Cardiomyopathy Diagnosis

Jan 13, 2025 by
Will Chu, CRTonline.org

A new study suggests the introduction of personalized thresholds for diagnosing hypertrophic cardiomyopathy (HCM) in proposals that challenge long-standing one-size-fits-all diagnostic standards.

1-3 of 4095 results
1 2 3 4 5 Next »

Most Viewed Pages

Treatment of Aortic Regurgitation

King and I | S5 E7 | Insights from the EARLY TAVRY Study

Study Proposes Demographic-Based Approach to Improve Hypertrophic Cardiomyopathy Diagnosis

Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

Biolimus DCB Non-Inferior to Paclitaxel DCB in Treating DES-ISR: BIO ASCEND ISR Trial

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

HF Patients With Prior MI See No Clinical Benefit from Revivent TC Anchor System vs Medical Therapy Alone: ALIVE Trial

Study Proposes Demographic-Based Approach to Improve Hypertrophic Cardiomyopathy Diagnosis

Most Viewed Pages

Explore the Site

Stay Connected